BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

Irreversible inhibitors of Bruton tyrosine kinase (BTK), pioneered by ibrutinib, have become breakthrough drugs in the treatment of leukemias and lymphomas. Resistance variants (mutations) occur, but in contrast to those identified for many other tyrosine kinase inhibitors, they affect less frequent...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Estupiñán, H. Yesid, Wang, Qing, Berglöf, Anna, Schaafsma, Gerard C. P., Shi, Yuye, Zhou, Litao, Mohammad, Dara K., Yu, Liang, Vihinen, Mauno, Zain, Rula, Smith, C. I. Edvard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102192/
https://ncbi.nlm.nih.gov/pubmed/33526860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-021-01123-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak